Kisspeptin
Reproductive signaling peptide | Hormones • Fertility • Reproductive Biology
Common names: reproductive signaling · fertility · hormones
- Evidence searched through
- August 2026
- Last reviewed
- August 22, 2026
- Current version
- 1.0
4V Take
What the research shows.
Kisspeptin clearly affects reproductive hormone signaling in humans. Studies show it can raise key reproductive hormones, and it has been studied in fertility settings. What is still unclear is how useful it will be as a long-term treatment or for the broader wellness claims you may see online.
Explore the evidenceResearch Interest
Why are people interested?
Researchers are studying Kisspeptin across Reproductive Hormone Signaling • Fertility and Sexual-Brain Processing • Alternative Delivery. These are areas of research interest, not guaranteed outcomes.
Evidence Context
What have researchers looked at?
This approved record brings together the research settings represented in its selected public sources. Evidence settings answer different questions, so human, animal, laboratory, and research-review findings stay distinct.
Current research context
Research stage describes the maturity of the current topic record. Source context describes the evidence settings represented in the selected public sources below; they are not interchangeable.
- Research stage
- Developing
- Selected source context
- Human
At a Glance
Research snapshot.
- 01Human Research
Yes, multiple controlled studies - 02Research Stage
Developing - 03Most Studied Areas
Reproductive Hormone Signaling • Fertility - 04Additional Research
Sexual-Brain Processing • Alternative Delivery - 05Current Research
Active
Research Pathway
Follow the questions.
Choose a pathway to read its approved 4V Take. Each view stays focused on one question at a time.
4V Take
Kisspeptin is a signaling peptide that sits near the top of the reproductive hormone pathway. It stimulates GnRH signaling, which can increase LH and FSH and influence testosterone, ovarian function, and reproductive activity. Human studies clearly show that this pathway responds to kisspeptin, although therapeutic applications vary by formulation and setting.
- Evidence bucket
- human clinical
- Research stage
- developing clinical
- Route / format
- kisspeptin peptides; route varies by study
Explore the evidence
human RCT
Kisspeptin-54 stimulates the HPG axis in human males
human RCT
Kisspeptin-54 in hypothalamic amenorrhea with tachyphylaxis
human controlled study
Chronic subcutaneous kisspeptin-10 for 12 days in healthy men
4V Take
Yes. Controlled human studies in men show that kisspeptin can raise LH and increase testosterone, sometimes quite clearly in acute physiology experiments. What that proves is that the reproductive hormone pathway responds to kisspeptin. It does not by itself establish kisspeptin as a proven long-term replacement therapy for low testosterone.
- Evidence bucket
- human clinical
- Research stage
- developing clinical
- Route / format
- primarily IV/experimental kisspeptin-10 studies
Explore the evidence
human controlled study
Chronic subcutaneous kisspeptin-10 for 12 days in healthy men
human RCT
Kisspeptin-54 stimulates the HPG axis in human males
human RCT
Kisspeptin-54 in hypothalamic amenorrhea with tachyphylaxis
4V Take
Yes. Kisspeptin-54 has been used in human IVF research to trigger oocyte maturation, followed by fertilization, embryo transfer, pregnancies, and live births in the study programs. This is genuine clinical research rather than just animal or laboratory evidence. The important boundary is that these controlled kisspeptin-54 IVF protocols should not be treated as interchangeable with every kisspeptin formulation or dosing approach.
- Evidence bucket
- human clinical
- Research stage
- developing clinical
- Route / format
- subcutaneous kisspeptin-54 in IVF
Explore the evidence
human clinical
Kisspeptin-54 triggers egg maturation during IVF
human Phase 2
Kisspeptin-54 in IVF patients at high risk of OHSS
human RCT
Kisspeptin-54 stimulates the HPG axis in human males
4V Take
Kisspeptin-10 and kisspeptin-54 activate the same receptor pathway, but they are not interchangeable evidence packages. They differ in peptide length, pharmacokinetics, dosing patterns, and the applications in which they have been studied. Much of the IVF evidence involves kisspeptin-54, while several male hormone studies involve kisspeptin-10.
- Evidence bucket
- mixed
- Research stage
- developing clinical
- Route / format
- kisspeptin-10 versus kisspeptin-54
Explore the evidence
human RCT
Kisspeptin-54 stimulates the HPG axis in human males
human RCT
Kisspeptin-54 in hypothalamic amenorrhea with tachyphylaxis
human controlled study
Chronic subcutaneous kisspeptin-10 for 12 days in healthy men
4V Take
Yes, repeated kisspeptin exposure can become less effective in some settings because the reproductive signaling pathway can desensitize. Human studies in hypothalamic amenorrhea showed marked tachyphylaxis with frequent dosing, while different administration patterns produced more sustained responses. Desensitization is a signaling adaptation, not the same thing as toxicity.
- Evidence bucket
- human clinical
- Research stage
- developing clinical
- Route / format
- repeated experimental administration
Explore the evidence
human RCT
Kisspeptin-54 stimulates the HPG axis in human males
human RCT
Kisspeptin-54 in hypothalamic amenorrhea with tachyphylaxis
human controlled study
Chronic subcutaneous kisspeptin-10 for 12 days in healthy men
4V Take
Kisspeptin clearly activates the reproductive hormone axis in humans, but it is not established as a long-term replacement treatment for chronic male hypogonadism. Most direct evidence shows short-term or subacute hormone responses rather than durable clinical outcomes over long periods. 4V can compare that evidence with other approaches without turning an interesting pathway into a proven treatment claim.
- Evidence bucket
- human clinical
- Research stage
- early clinical
- Route / format
- chronic therapeutic use
Explore the evidence
human RCT
Kisspeptin-54 stimulates the HPG axis in human males
human RCT
Kisspeptin-54 in hypothalamic amenorrhea with tachyphylaxis
human controlled study
Chronic subcutaneous kisspeptin-10 for 12 days in healthy men
Selected Sources
Explore the evidence.
Open an approved public source to inspect its study context, limitations, and original record where available.
human RCT
Kisspeptin-54 stimulates the HPG axis in human males
2005 · PMID: 16174713 · peer reviewed
human RCT
Kisspeptin-54 in hypothalamic amenorrhea with tachyphylaxis
2009 · PMID: 19820030 · peer reviewed
human controlled study
Chronic subcutaneous kisspeptin-10 for 12 days in healthy men
2026 · PMID: 42549827 · peer reviewed
human clinical
Kisspeptin-54 triggers egg maturation during IVF
2014 · PMID: 25036713 · peer reviewed
human Phase 2
Kisspeptin-54 in IVF patients at high risk of OHSS
2015 · PMID: 26192876 · peer reviewed
Research Status
Living research, deliberately tracked.
- Evidence searched globally through:
- August 2026
- Last reviewed
- August 22, 2026
- Version
- 1.0
What Changed
Current record.
No later approved public release is available beyond the current topic record.
Evidence Boundaries
What are researchers still working out?
Study settings, measures, and limitations matter. A mechanism does not establish an outcome, animal or laboratory findings do not establish a human benefit, and a small study does not create consensus. Open each selected source for the approved record behind its finding.
Save / Follow
Keep this research close.
Save and Follow remain private account preferences. Following does not activate monitoring or notifications.
Loading member research actions.